Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Personalis Inc (NQ: PSNL )

4.790 -0.140 (-2.84%)
Streaming Delayed Price Updated: 10:28 AM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 166,656
Open 4.900
Bid (Size) 4.780 (1)
Ask (Size) 4.790 (1)
Prev. Close 4.930
Today's Range 4.710 - 4.900
52wk Range 0.8906 - 7.200
Shares Outstanding 48,518,901
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
From Personalis, Inc.
Via Business Wire
Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment
Tempus AI is a hot healthcare stock that investors should be aware of. It is using AI to pursue "precision medicine", especially in cancer research. 
Via MarketBeat
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence

Performance

YTD
+134.80%
+134.80%
1 Month
-8.24%
-8.24%
3 Month
+299.17%
+299.17%
6 Month
+249.64%
+249.64%
1 Year
+280.16%
+280.16%

More News

Read More
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Why Tempus AI Stock Skyrocketed Nearly 22% Today
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Assessing Personalis: Insights From 4 Financial Analysts
Via Benzinga
Breaking Down Personalis: 4 Analysts Share Their Views
Via Benzinga
4 Analysts Have This To Say About Personalis
Via Benzinga
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Personalis and Tempus Announce Expanded Collaboration
From Personalis, Inc.
Via Business Wire
PSNL Stock Earnings: Personalis Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Personalis Reports Second Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
From Personalis, Inc.
Via Business Wire
Personalis to Announce Second Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
From Personalis, Inc.
Via Business Wire
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
From Personalis, Inc.
Via Business Wire
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
From Personalis, Inc.
Via Business Wire
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
From Personalis, Inc.
Via Business Wire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
From Personalis, Inc.
Via Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
PSNL Stock Earnings: Personalis Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Personalis Reports First Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Announce First Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.